Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Santhera Finalizes Vamorolone Filings And Now Seeks Funds

Seeking Priority Review For DMD Drug

31 Oct 2022

• By Kevin Grogan

Eklund_Dario_1200 — CEO Dario Eklund • Source: Santhera

Related Content

Santhera Pulls EU Filing For Failed DMD Candidate

11 Nov 2020

With Duchenne Filing Due, Santhera Moves Vamorolone Into Becker Muscular Dystrophy

22 Aug 2022

Santhera's Transformation Should Turn Investors' Heads

28 Jan 2022

Related Companies

Santhera Pharmaceuticals

Reveragen BioPharma, Inc.

Additional Topics

Business Strategies Rare Diseases Sales & Earnings Commercial Financing Regulation

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.